TNGX נכסי החברה Tango Pharma
Tango Therapeutics (TNGX) supports the development of targeted cancer therapies via synthetic lethality and the success of the TNG908 inhibitor through alliances with pharma behemoths to diversify risks. The market trend of total asset value, which currently stands at 655.99, serves as a capital indicator. Tango Therapeutics (TNGX) generates revenue by creating innovative therapy methods, leveraging genetic analysis and strategic biopharmaceutical collaborations.
%3A%20%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%9E%D7%A6%D7%A8%D7%A4%D7%99%D7%99%D7%9D%20%D7%A9%D7%9C%20%D7%94%D7%97%D7%91%D7%A8%D7%94&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_TNGX_-_Tango-Therapeutics_-_Aggregate-Company-Assets "סך נכסי הפעילות העסקית Tango Therapeutics Corp (TNGX): לתקופה 04.07.2022 - 29.10.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Tango Pharma (TNGX)
A comparative analysis of total assets allows an investor to evaluate capital efficiency relative to the WACC rate to eliminate the risk of business value destruction. The current value of 655.99, calculated inversely via ROA, reflects the volume of resources allocated to the development of the synthetic lethality platform and TNG908 clinical trials, which is clearly confirmed by the history of controlled resources for Tango Therapeutics (TNGX).